Detalhe da pesquisa
1.
Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment naïve patients and non-responders to fumaric acid esters: Results from parts II and III of a randomised, active-comparator-controlled phase IIIb trial (POLARIS).
Br J Dermatol
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38133615
2.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 89(2): 274-282, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37019386
3.
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Drug Saf
; 47(1): 39-57, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906417
4.
A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting.
Eur J Dermatol
; 33(1): 25-33, 2023 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37154812